-
Chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes
Chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes
-
Chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes
Chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes
Chloroquine and hydroxychloroquine are being investigated worldwide for their potential to treat coronavirus disease (COVID-19). However, efficacy in treating COVID-19 is yet to be shown in studies.
-
Update on treatments and vaccines against COVID-19 under development
Update on treatments and vaccines against COVID-19 under development
-
Update on treatments and vaccines against COVID-19 under development
Update on treatments and vaccines against COVID-19 under development
Supporting the rapid development and approval of effective and safe treatments for and vaccines against COVID-19 is EMA’s top priority. The Agency provides an update on therapeutics and vaccines under development against the disease.
-
The future of regulatory science in the EU
The future of regulatory science in the EU
-
The future of regulatory science in the EU
The future of regulatory science in the EU
EMA has published its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines.
-
COVID-19: latest updates
COVID-19: latest updates
-
COVID-19: latest updates
COVID-19: latest updates
Keep up to date with the latest information from EMA on the COVID-19 pandemic.
